Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1001/archdermatol.2012.848 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Exosomes for Aesthetic Dermatology: A Comprehensive Literature Review and Update.
J Cosmet Dermatol
January 2025
Clinical Research Center of the Carolinas, Charleston, South Carolina, USA.
Background: Exosomes are nanoscale vesicles derived from various cell types and tissues that have many potential applications, generating great interest from researchers. One particularly intriguing application of exosomes is their use as a direct therapeutic for aesthetic indications. Several studies and case reports have explored the impact of exosomes for numerous cosmetic concerns but a consensus on the outcomes of these studies has not been established.
View Article and Find Full Text PDFBaricitinib for the treatment of severe alopecia areata: results from a 52-week multicenter retrospective real-world study.
J Dermatolog Treat
December 2025
Dermatology Unit, IRCCS Humanitas Research Hospital, Milan, Italy.
Baricitinib, a JAK 1/2 inhibitor, is approved for treating severe alopecia areata (AA). This study aimed to evaluate the long-term effectiveness and safety of baricitinib in a real-world setting over 52 weeks. This multicenter retrospective study included 96 adult patients diagnosed with severe AA from 11 Italian Dermatology Units.
View Article and Find Full Text PDFThe Relationship Between Nutrition Habits, BMI, Anxiety, and Seborrheic Dermatitis.
J Cosmet Dermatol
January 2025
Dermatology and Venereology Department, Eskisehir Osmangazi University, Eskisehir, Turkey.
Background: Seborrheic dermatitis (SD) is a chronic, inflammatory disease characterized by unknown etiopathogenesis. It affects skin areas rich in sebaceous glands. There are strong data on the relationship between nutrition habits, body mass index (BMI), psychoemotional status, and sebaceous gland diseases such as acne, rosacea, and androgenetic alopecia.
View Article and Find Full Text PDFDissecting Cellulitis of the Scalp.
Kans J Med
November 2024
Department of Dermatology, The University of Missouri-Kansas City School of Medicine, Kansas City, Missouri.
Treatment of discoid lupus erythematosus scarring alopecia with deucravacitinib: A case report.
SAGE Open Med Case Rep
January 2025
Division of Dermatology, Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada.
Discoid lupus erythematosus is a chronic, recurring, autoimmune skin disease causing annular, scarring plaques on the head and neck. Deucravacitinib, a tyrosine kinase 2 inhibitor in the Janus kinase inhibitor family, represents an emerging treatment option in systemic lupus erythematosus with potential applicability to discoid lupus erythematosus. We describe a 48-year-old woman with multiple treatment-refractory scalp plaques and associated alopecia treated with deucravacitinib.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!